In 2016 Sanofi only had two commercially significant marketed products for skin diseases – Allegra and Targocid – which generated $31m and $8m respectively.

These modest revenues meant the company commanded a market share of just 0.27%, which made it the 25th placed company in the therapy area.

However, between 2016 and 2023 Sanofi’s revenue from dermatology is forecast to increase at a compound annual growth rate (CAGR) of 83.6%, peaking at $2.8 billion in 2023.

This will make it the fourth largest company in the therapy area, with a market share of 10.3%.

Growth driven by Dupixent

graph

In March 2017 Sanofi received FDA approval for Dupixent – the first biologic drug to treat moderate-to-severe atopic dermatitis.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

It will be marketed by Sanofi and Regeneron, with the majority of the revenue going to Sanofi.

In 2017 Sanofi is forecast to generate $102 million from Dupixent, and between 2017 and 2023 this will increase at a CAGR of 154%, peaking at $2.75 billion in 2023.

With Sanofi’s and Regeneron’s 2023 Dupixent revenues combined, the drug will be the second most commercially successful product in dermatology, with an annual revenue of $3.6 billion, trailing behind only Novartis’s Cosentyx.